Glymphatic Pathway in Brain Imaging
Launched by PARACELSUS MEDICAL UNIVERSITY · Aug 30, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Glymphatic Pathway in Brain Imaging," is studying how a special contrast agent, called Gadolinium-based contrast agent (GBCA), moves through different parts of the brain. Researchers want to understand how the way this contrast agent spreads can be related to certain brain diseases. This information could help improve brain imaging techniques and lead to better diagnoses.
If you're considering participating, you must be between the ages of 65 and 74 and have a medical reason for needing the GBCA. You also need to be able to provide written consent and not have any allergies to the agent. During the trial, participants will undergo MRI scans with the contrast agent, which is a common procedure used to get detailed images of the brain. It's important to note that anyone with certain health issues that prevent them from having an MRI will not be eligible for this study. Overall, this trial aims to enhance our understanding of brain health and disease through advanced imaging techniques.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Only patients with a clinical indication for GBCA
- • Written informed consent
- • No allergies to GBCA
- Exclusion Criteria:
- • Contraindications for MRI
About Paracelsus Medical University
Paracelsus Medical University is a pioneering institution dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates cutting-edge scientific inquiry with practical applications in healthcare. Its commitment to enhancing patient outcomes is reflected in its rigorous study designs and adherence to ethical standards. By fostering a dynamic environment for researchers and clinicians alike, Paracelsus Medical University plays a crucial role in the development of novel therapeutic approaches and the translation of research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nuremberg, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials